Biomedical presented their study results at the 2010 ASCO Annual
Meeting in Chicago, regarding its serum DNA
blood tests. The DNA assays may be the newest
diagnostic and prognostic approach in detecting breast and
prostate cancer. The high numbers for sensitivity and specificity
significantly outperformed the published accuracy data for current
methods. By employing proprietary algorithms, developed
by Chronix researchers, tests can detect and analyze, as well as
identify cancer-related bits of DNA that
are released by apoptotic cells into the bloodstream. However, only a
few regions consistently show apoptotic DNA in the serum. These
regions, named 'hotspots,' are specific to the type of cancer –
only 29 breast cancer 'hotspots' and 32 prostate cancer 'hotspots' to
be exact. "By focusing on these blood-born genomic
'hotspots,' we can reliably detect the presence of cancer without
having to first isolate or analyze tumor cells," said Howard
Urnovits, Ph.D., co-author of the study, and Chief Executive Officer
of Chronix. He continued by explaining that Chronix tests for cancers
would allow doctors to diagnose cancer at its earliest stages,
allowing for greater care and optimize treatment using patients'
disease-specific genomic fingerprints. The study
involved 575 individuals: 200 healthy patients, 178 with early
cancer, and 197 with invasive prostate cancer were employed.
Chronix assays detected the breast cancer with a 100% specificity and
92% sensitivity, and prostate cancer with the same 100% specificity
and 92% sensitivity. Current practices result in comparatively lower
numbers, however, they cannot be directly compared.
an overall sensitivity of 75% and specificity of 92.3%, as found by a
large study of U.S. mammography screenings.The PSA (prostate specific
antigen) test, currently used to detect prostate cancer, has an
overall 85% sensitivity and 25-35% specificity. The future use of
Chronix to detect cancer may reduce the current rate of false
negative and false positive results, leading to an improvement in all
areas of health care, ranging from patient outcomes to health care
costs."These new data, although early, provide further
evidence that Chronix's proprietary serum DNA assays may represent a
new diagnostic and prognostic platform that can identify cancer
earlier and more accurately than is currently possible," states
breast cancer expert Steven Narod, M.D., F.R.C.P.C. This
is not the first time Chronix released studies concerning new
diagnostic approaches to diseases. Previous studies showed that the
Chronix approach can identify the presence/absence of active disease
in multiple sclerosis patients, as well as the detection of BSE, or
mad cow disease, in veterinary applications.Many look to
these encouraging findings to service clinical researchers, as well
as cancer patients. The future use of Chronix assays may in fact
increase the survival rate among patients.
quote: Case in point Beta Blockers. The FDA kept them off the market for ~10 years then they declare we are able to save 250,000 a year. However, if they do the math 10x250,000 2.5 million people died from the FDA stepping in and preventing people that are already dying from getting a drug that could save their life.
quote: Leading edge medicine costs money. Otherwise it would never get developed in the first place.